Abstract 1893: Impact of the Glu298Asp Polymorphism of the Endothelial Nitric Oxide Synthase Gene on Prognostic Parameters and on Survival in 684 Consecutive Patients With Stable Congestive Heart Failure
Previous studies have suggested a possible impact of the Glu298Asp polymorphism of the endothelial nitric oxyde synthase gene (NOS) polymorphism on survival of patients with congestive heart failure (CHF), with a better survival rate in Asp298 patients, in particular in patients with non-ischemic cardiomyopathy. We studied 684 consecutive Caucasian patients with optimal CHF treatment (renin-angiotensin system inhibitors: 98% and beta-blocker: 91%). All the patients, except 15, had a coronarography. Clinical characteristics were similar between sub-groups of patients divided according to their NOS gene polymorphism (see Table⇓, NS for all, mean±SD except for BNP median [interquartile range]). During a follow-up period of 1200 days, there were 158 cardiac related deaths and 1 patient was lost to follow-up. There was no impact of this polymorphism on survival in the whole population, nor in subgroups of patients divided according to etiology (Figure⇓).
In conclusion, in our large population of Caucasian CHF patients, Glu298Asp NOS gene polymorphism had no effect on prognostic parameters and on survival.